Table 3. Associations of finasteride concentrations with prostate cancer risk in PCPT, overall and stratified by cancer grade.

		All Cancer		(Low) Gleason 2–6		(High) Gleason 7–10
Finasteride Concentrations	N control	N case	OR (95% CI)	N case	OR (95% CI)	N case	OR (95% CI)
1 to <10 ng/mL	91	87	ref	51	ref	31	ref
10 to <20 ng/mL	154	123	0.76 (0.51–1.12)	73	0.78 (0.49–1.23)	44	0.74 (0.43–1.28)
20 to <30 ng/mL	128	136	1.09 (0.73–1.62)	81	1.13 (0.72–1.79)	51	1.11 (0.65–1.89)
30 to <40 ng/mL	123	99	0.74 (0.49–1.12)	60	0.78 (0.48–1.26)	35	0.72 (0.41–1.28)
40 to <50 ng/mL	84	72	0.81 (0.52–1.28)	32	0.63 (0.36–1.11)	36	1.13 (0.63–2.03)
50+	95	76	0.82 (0.52–1.29)	41	0.79 (0.46–1.34)	32	0.95 (0.52–1.73)
p-trend			0.42		0.22		0.73
Continuous, per 10ng/mL	675	593	0.97 (0.91–1.04)	338	0.96 (0.89–1.04)	229	1.00 (0.93–1.09)

Odds ratios are adjusted for age, race (white vs black vs others), time of day of blood draw, and family history of prostate cancer.